复方甘草酸苷片联合伐昔洛韦治疗带状疱疹疗效观察

目的探讨复方甘草酸苷片联合伐昔洛韦治疗带状疱疹的疗效。方法选取2011年1月至2012年3月收治的带状疱疹患者共76例,随机分为治疗组和对照组,其中治疗组采用复方甘草酸苷片联合伐昔洛韦治疗,而对照组仅用伐昔洛韦治疗。结果治疗组的平均止疱、止痛、结痂时间均明显短于对照组(P<0.05);治疗组患者的总有效率明显高于对照组,差异具有统计学意义(94.74%vs.68.42%,P<0.05)。结论复方甘草酸苷片联合伐昔洛韦治疗带状疤疹可明显地缩短患者的止痛、止疱和结痴时间,迅速消退皮损及缓解疼痛,及早改善患者的临床症状,且不良反应少。     

2型糖尿病合并带状疱疹神经痛患者红光照射联合药物治疗的效果观察

目的：探讨红光照射联合药物治疗2型糖尿病合并带状疱疹神经痛患者的临床效果。方法将100例糖尿病合并带状疱疹神经痛患者按入院时间先后顺序随机分为观察组和对照组各50例。对照组遵医嘱采用阿昔洛韦治疗及专科护理干预,观察组在对照组治疗的基础上加用红光照射,7 d为1个疗程,2个疗程结束时比较两组的平均止疱时间、结痂时间、疼痛缓解时间、疼痛基本消失时间和临床疗效。结果观察组的平均止疱时间、结痂时间、疼痛缓解时间、疼痛基本消失时间均较对照组缩短（P<0.05）;观察组临床疗效明显好于对照组（P<0.05）。结论2型糖尿病合并带状疱疹神经痛患者在药物治疗及护理干预的基础上,增加红光照射,疗效显著。     

更昔洛韦联合匹多莫德治疗带状疱疹疗效观察

目的观察更昔洛韦联合匹多莫德治疗带状疱疹疗效。方法将140例带状疱疹患者,随机分为观察组和对照组各70例。治疗组给予更昔洛韦联合匹多莫德治疗,对照组给予更昔洛韦治疗,疗程结束后对比分析两组治疗效果。结果两组患者治疗后疼痛消失时间、水疱结痂时间、皮损愈合时间的差异有统计学意义(P<0.05);观察组治疗总有效率为98.57%,对照组治疗总有效率为88.57%,差异有统计学意义(P<0.05)。结论两组患者治疗过程中未观察到明显的不良反应。     

盐酸伐昔洛韦联合醋酸泼尼松治疗带状疱疹效果观察

目的探讨盐酸伐昔洛韦联合醋酸泼尼松治疗带状疱疹的效果。方法选取2016年6月至2017年12月带状疱疹患者90例,依据治疗方案分为观察组与对照组,每组45例。对照组给予盐酸伐昔洛韦治疗,观察组给予盐酸伐昔洛韦联合醋酸泼尼松治疗。比较两组患者症状改善时间及治疗前后VAS疼痛评分,记录后遗神经痛发生情况。结果观察组止疱时间、止痛时间、水疱开始结痂时间、水疱全部结痂时间和皮损全部愈合时间少于对照组(P0.05)。治疗7 d,两组VAS疼痛评分均较治疗前下降(P0.05),且观察组VAS疼痛评分低于对照组(P0.05)。治疗30、90 d,两组VAS疼痛评分比较,差异未见统计学意义(P0.05)。治疗30 d,观察组发生带状疱疹后遗神经痛2例,对照组3例。结论盐酸伐昔洛韦联合醋酸泼尼松治疗带状疱疹,可缓解神经痛症状,使初期皮损较快愈合。     

伐昔洛韦联合氦氖激光治疗带状疱疹的效果

目的探讨伐昔洛韦联合氦氖激光治疗带状疱疹的效果。方法选择2012年3月至2013年3月皮肤科带状疱疹患者88例,随机分为两组,观察组44例给予伐昔洛韦联合氦氖激光治疗,对照组44例单纯给予伐昔洛韦口服治疗。比较两组治疗15 d后的疗效。结果观察组治疗总有效率为97.7%,高于对照组（86.4%）,差异有统计学意义（P〈0.05）。结论联合应用伐昔洛韦和氦氖激光治疗带状疱疹具有较好的临床效果,可消退皮损,改善神经疼痛的不良症状,减轻患者痛苦,提高生活质量。     

伐昔洛韦片联合复方黄柏液湿敷治疗带状疱疹的临床效果

目的探讨伐昔洛韦片联合复方黄柏液湿敷治疗带状疱疹的临床效果。方法选择82例带状疱疹患者为研究对象,随机将其分为对照组和观察组,每组41例。对照组行伐昔洛韦片治疗,观察组行伐昔洛韦片联合复方黄柏液湿敷治疗。比较两组患者的治疗效果。结果治疗后,观察组带状疱疹皮疹评分以及VAS评分低于对照组(P<0.05);治疗后,观察组IL-2、IL-6、IL-8及PGE2水平低于对照组(P<0.05);观察组的临床治疗总有效率高于对照组(P<0.05)。结论伐昔洛韦片联合复方黄柏液湿敷治疗带状疱疹效果确切,可有效改善患者临床症状,促进患者尽快康复,值得临床推广。     

氦氖激光联合伐昔洛韦治疗额面部带状疱疹的疗效观察

目的:探讨氦氖激光联合伐昔洛韦对额面部带状疱疹患者疼痛程度及生活质量的影响。方法:选取2016年6月~2017年6月我院收治的额面部带状疱疹患者86例,随机分为对照组和观察组各43例。对照组给予伐昔洛韦治疗,观察组给予伐昔洛韦+氦氖激光治疗,比较两组治疗前后疼痛程度(VAS)及生活质量(GQOL-74)评估情况。结果:治疗前,两组VAS及GQOL-74评分比较差异不显著(P0.05);治疗后,观察组VAS评分低于对照组,GQOL-74评分高于对照组(P0.05)。结论:氦氖激光联合伐昔洛韦治疗额面部带状疱疹,可有效缓解患者疼痛,改善生活质量,促进早期康复,预后较佳。     

伐昔洛韦联合半导体激光治疗带状疱疹的疗效

目的观察伐昔洛韦联合半导体激光治疗带状疱疹的疗效。方法将70例带状疱疹患者随机分为治疗组和对照组各35例。治疗组给予伐昔洛韦0．3g,bidpo,半导体激光照射受损的神经根部和皮损部位,疗程10d。对照组给予伐昔洛韦片0．3g,bidpo,疗程10d。结果治疗组总有效率显著高于对照组（91．4％VS71．4％,P〈0.01）;治疗组患者临床体征消退时间明显短于对照组（均P〈0．05）。结论伐昔洛韦联合半导体激光治疗带状疱疹优于单纯药物治疗,效果显著。     

硼酸湿敷联合红外线照射辅助治疗带状疱疹的观察及护理

目的研究硼酸湿敷联合红外线照射同时采取有效的护理干预辅助治疗带状疱疹的疗效。方法将358例门诊带状疱疹患者随机分为对照组和观察组,对照组172例,观察组186例,两组均采用相同的药物治疗。对照组采用常规护理措施和健康教育。观察组采用硼酸湿敷联合红外线照射与护理干预辅助措施,比较两组疗效。结果观察组的有效率为94.6%,对照组的有效率为84.3%,两组比较差异有统计学意义(P0.05),观察组的皮疹消退时间和疼痛消退时间都明显短于对照组(P0.05)。结论硼酸湿敷联合红外线照射并采取有效的护理干预辅助的治疗方法有效缓解了患者的疼痛,缩短结痂脱落时间,增加患者战胜疾病的信心。     

更昔洛韦治疗眼部带状疱疹临床效果观察

目的探讨更昔洛韦治疗眼部带状疱疹的临床效果。方法将眼部带状疱疹患者52例分为两组,治疗组28例用更昔洛韦针剂0.25 g/d,静脉滴注,对照组24例用阿昔洛韦0.5 g/d,静脉滴注,均连续使用10天,比较两组临床疗效,主要观察项目及不良反应。结果治疗组有效率(92.9%)明显高于对照组(58.3%),带状疱疹的止痛时间、止疱时间及结痂时间均明显短于对照组,差异均有统计学意义(P<0.05)。两组均无任何眼部后遗症,不良反应均轻微。结论更昔洛韦治疗眼部带状疱疹具有疗效好、见效快、症状改善显著,值得临床推广应用。     

优质护理干预措施在单纯疱疹病毒性角膜炎的应用效果分析

目的探讨优质护理干预措施在单纯疱疹病毒性角膜炎的应用效果。方法选取单纯疱疹病毒性角膜炎患者92例作为研究对象,按随机数表法分为对照组和观察组各46例。2组均行常规治疗,对照组行常规护理,观察组在对照组基础上实施优质护理干预,比较2组患者单纯疱疹病毒性角膜炎症状消失时间、不良情况及复发情况。结果干预后,观察组视力情况高于对照组(P0.05);观察组皮疹消失时间、眼部损害消失时间及疼痛消失时间均短于对照组(P0.05),观察组不良反应率低于对照组(P0.05)。结论在单纯疱疹病毒性角膜炎患者治疗过程中实施优质护理干预效果较好,可有效提高患者视力,缩短症状消失时间,减少不良反应。     

局部紫外线联合阿昔洛韦治疗带状疱疹的疗效观察

目的观察局部紫外线照射联合阿昔洛韦治疗带状疱疹的临床疗效。方法138例带状疱疹患者分为2组。治疗组用阿昔洛韦口服治疗加局部紫外线照射;对照组单用阿昔洛韦治疗带状疱疹。结果治疗组有效率（97．92％）明显高于对照组（P〈0．05）,带状疱疹后遗神经痛发生率亦比对照组明显降低。结论局部紫外线联合阿昔洛韦治疗带状疱疹起效快,疗程短,疗效显著,且能防止后神经痛的发生。     

Clinical Science (43)

Valaciclovir: a review of its use in the management of herpes zoster. (Adis International Limited, Auckland, New Zealand) Drugs 2000;59:1317–1340. This study compared the effectiveness of valaciclovir (1000 mg 3 times daily for 7 days) and aciclovir (800 mg 5 times daily for 7 days) in controlling the symptoms of acute herpes zoster. Valaciclovir was found to alleviate zoster‐associated pain and postherpetic neuralgia significantly faster than aciclovir. A 14‐day regimen of valaciclovir showed no significant advantage over the 7‐day regimen. A smaller trial in Japanese patients focusing primarily on the cutaneous (rash) signs of herpes zoster confirmed the similar efficacy of valaciclovir and aciclovir in the 7‐day regime. Valaciclovir and aciclovir demonstrated similar efficacy for the control of cutaneous lesions and ocular complications in patients with zoster ophthalmicus. Starting treatment later than 72 h after rash onset did not significantly reduce the beneficial effect of valaciclovir on the duration of zoster‐associated pain, suggesting that valaciclovir might be effective when given later than previously thought. However, valaciclovir should ideally be given as soon as possible after symptoms appear. Valaciclovir was well tolerated with nausea and headache as being the most commonly reported adverse events. The adverse events profile of the agent was similar to that seen with aciclovir or famciclovir. Conclude that the efficacy of valaciclovir for the treatment of herpes zoster has been confirmed and extended by follow‐up studies in herpes zoster ophthalmicus, in Japanese patients, and in the wider primary care setting. Valaciclovir is at least equivalent to, and better in certain parameters than, aciclovir and appears to have similar efficacy to famciclovir 500 mg 3 times daily. Comment by Susan Anderson, MD. This is a review article on the antiviral drug valaciclovir. The varicella zoster virus (VZV) is commonly treated with the antiviral drug aciclovir. However, aciclovir has a low oral bioavailability that limits its efficacy in the treatment of herpes zoster. Valaciclovir was developed in order to have a more readily absorbed oral antiviral drug. When valaciclovir was compared to aciclovir in a large study, it was noted that valaciclovir was as effective in controlling the symptoms of acute herpes zoster. It was also noted valaciclovir alleviated zoster associated pain and postherpetic neuralgia significantly faster than aciclovir. Also, there was no significant advantage of treating valaciclovir 14 days versus 7 days; therefore, a 7‐day regimen is recommended. In a smaller trial from Japan that focused primarily on the cutaneous (rash) signs of herpes zoster, there was also confirmation of similar efficacy of aciclovir and valaciclovir in a 7‐day regimen. The similarity in efficacy was not only for cutaneous lesions but also for ocular complications in patients with zoster ophthalmicus. In a large controlled trial, they compared valaciclovir and famciclovir. This showed similar efficacy in resolution of acute herpes zoster rashes shortening the duration of postherpetic neuralgia. It was purposed in the article that the therapeutic window for beneficial treatment with valaciclovir and zoster associated pain may be wider that previously though. It is still recommended that valaciclovir be ideally given as soon as possible after symptoms appear. However, starting treatment after 72 hours after rash onset did not significantly reduce the beneficial effect of the valaciclovir on duration of zoster associated pain. Valaciclovir is known to be well tolerated with nausea and headache being the most commonly reported adverse events. The adverse events profile of valaciclovir is similar to aciclovir or famciclovir. The purpose of this review was to present an overview of the pharmacodynamic/pharmacokinetic properties and therapeutic efficacy in the assessment of pain in herpes zoster in comparison with known agents of aciclovir, famciclovir, and/or placebo. It is concluded that valaciclovir is an efficacious agent in the treatment of herpes zoster and herpes zoster ophthalmicus. It's at least as efficacious as aciclovir and has similar efficacy to famciclovir. It is well tolerated with a similar side effect profile as aciclovir and famciclovir.     

护理干预预防眼底血管荧光造影不良反应的临床效果观察

目的探讨护理干预预防眼底血管荧光造影产生不良反应的临床效果。方法将120例行眼底血管荧光造影检查的患者随机分为观察组和对照组各60例,对照组患者给予常规护理,观察组患者在常规护理的基础上给予护理干预,观察2组患者的不良反应发生情况。结果观察组患者经护理干预后不良反应发生率为8.3%,显著低于对照组患者的23.3%,组间差异有统计学意义（P〈0.05）。结论对行眼底血管荧光造影检查的患者实施护理干预能够有效预防不良反应的发生,降低不良反应发生率。     

梅花针联合阿昔洛韦治疗带状疱疹患者的临床效果及安全性

目的分析梅花针联合阿昔洛韦治疗带状疱疹患者的临床效果及安全性。方法将100例带状疱疹患者根据随机数字表法分为对照组(50例,阿昔洛韦)与试验组(50例,梅花针联合阿昔洛韦)。比较两组的临床效果。结果试验组的瘙痒缓解时间、退热时间、皮疹结痂时间、止疱时间及脱痂时间均短于对照组(P<0.05)。试验组的临床治疗总有效率高于对照组(P<0.05)。治疗后,两组的VAS评分及中医症状评分均降低,且试验组低于对照组(P<0.05)。试验组的不良反应总发生率低于对照组(P<0.05)。结论梅花针联合阿昔洛韦治疗带状疱疹患者的临床效果显著,有助于促进患者皮疹改善,缓解疼痛程度及中医症状,提高治疗安全性。     

系统化护理干预对急诊静脉输液不良反应及护理满意度的影响

目的探讨系统化护理干预措施对急诊静脉输液不良反应及护理满意度的影响。方法选择该院急诊科收治的146例急诊静脉输液患者,随机分成观察组和对照组各73例。其中对照组患者给予常规护理干预,观察组患者给予系统化护理干预,对比两组患者不良反应发生情况和护理的满意度。结果两组患者经不同的护理方式干预后,观察组的护理满意度评分为(98.32±1.12)分,明显高于对照组的(76.54±2.38)分,差异有统计学意义(P0.05);观察组的静脉不良反应发生率为16.67%,明显低于对照组的46.58%,差异有统计学意义(P0.05)。结论对急诊静脉输液患者实施系统化护理干预,可明显降低不良反应发生率,提高患者护理满意度,值得在临床中推广应用。     

循证护理对浅表性血管瘤患儿不良反应及不良情绪的影响

目的探究循证护理对浅表性血管瘤患儿不良反应及不良情绪的影响。方法采用信封密封法将2019年4月~2020年2月期间我院收治的浅表性血管瘤婴幼儿66例分为两组,分别为对照组(n=33,常规护理干预)及观察组(n=33,循证护理),比较两组疗效、护理满意度、不良情绪及不良反应发生率。结果观察组总有效率高于对照组(90.91%vs 78.79%)(P<0.05);观察组不良反应发生率低于对照组(6.06%vs 24.24%)(P<0.05);观察组满意度高于对照组(93.94%vs 81.82%)(P<0.05)。干预后,两组SAS、SDS评分均较干预前降低,且观察组均较对照组低(P<0.05)。结论循证护理应用曲安奈德治疗婴幼儿浅表性血管瘤中,能够针对循证护理问题进行针对性护理,显著缓解不良情绪,降低不良反应发生率,值得推广。